| scholarly article | Q13442814 |
| P356 | DOI | 10.1017/S146114571100068X |
| P698 | PubMed publication ID | 21557880 |
| P50 | author | Paul M. Thompson | Q18387155 |
| Philip B. Ward | Q38544599 | ||
| Patrick Johnston | Q43122616 | ||
| P2093 | author name string | Amanda Baker | |
| Vaughan J Carr | |||
| Ulrich Schall | |||
| Martin Cohen | |||
| Paul E Rasser | |||
| Greg Peck | |||
| P2860 | cites work | Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis | Q46059619 |
| Dynamics of gray matter loss in Alzheimer's disease. | Q46191030 | ||
| Magnetic resonance imaging evaluation of the effects of ageing on grey-white ratio in the human brain. | Q48116199 | ||
| Progressive loss of cerebellar volume in childhood-onset schizophrenia | Q48417527 | ||
| Fully automatic segmentation of the brain in MRI. | Q48454728 | ||
| Gray matter abnormalities in subjects at ultra-high risk for schizophrenia and first-episode schizophrenic patients compared to healthy controls. | Q48516526 | ||
| Progressive grey matter atrophy over the first 2-3 years of illness in first-episode schizophrenia: a tensor-based morphometry study | Q48553507 | ||
| Cerebellar substructures and neurological soft signs in first-episode schizophrenia. | Q48561697 | ||
| Reduced volume of the cerebellar vermis in neuroleptic-naive schizophrenia | Q49060739 | ||
| Gyrification brain abnormalities associated with adolescence and early-adulthood cannabis use. | Q51858246 | ||
| Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. | Q51886500 | ||
| Cannabis use and brain structural alterations in first episode schizophrenia--a region of interest, voxel based morphometric study. | Q51894564 | ||
| Duration of prodromal phase and severity of volumetric abnormalities in first-episode psychosis | Q57403318 | ||
| Cerebellar posterior superior vermis and cognitive cluster scores in drug-naive patients with first-episode schizophrenia | Q80997128 | ||
| The role of the cerebellum in schizophrenia: an update of clinical, cognitive, and functional evidences | Q24644046 | ||
| The assessment and analysis of handedness: The Edinburgh inventory | Q26778476 | ||
| Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review | Q28238516 | ||
| A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM). | Q30328625 | ||
| Cerebral white matter: neuroanatomy, clinical neurology, and neurobehavioral correlates | Q30450267 | ||
| Eye-blink conditioning deficits indicate temporal processing abnormalities in schizophrenia | Q30481356 | ||
| A nonparametric method for automatic correction of intensity nonuniformity in MRI data | Q32061718 | ||
| Neuroimaging in cannabis use: a systematic review of the literature | Q33486183 | ||
| Mapping gray matter development: implications for typical development and vulnerability to psychopathology | Q33508041 | ||
| Abnormal cerebellar morphometry in abstinent adolescent marijuana users | Q33838292 | ||
| Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. | Q34174069 | ||
| Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study | Q34220050 | ||
| Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis | Q34585703 | ||
| Regional brain abnormalities associated with long-term heavy cannabis use. | Q34592700 | ||
| Cannabis use disorder: epidemiology and management | Q34975761 | ||
| Mapping cortical change in Alzheimer's disease, brain development, and schizophrenia | Q35925993 | ||
| Endocannabinoid functions controlling neuronal specification during brain development | Q37131370 | ||
| The role of the cerebellum in schizophrenia | Q37131862 | ||
| Cannabis, cannabinoids and schizophrenia: integration of the evidence | Q37160448 | ||
| The chronic effects of cannabis on memory in humans: a review | Q37561234 | ||
| Enhancement of MR images using registration for signal averaging | Q39464114 | ||
| Associative learning | Q41649149 | ||
| Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain | Q42451047 | ||
| Cerebellar grey matter deficits in first-episode schizophrenia mapped using cortical pattern matching | Q42969308 | ||
| Functional topography in the human cerebellum: a meta-analysis of neuroimaging studies | Q43530391 | ||
| Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients | Q43723165 | ||
| P433 | issue | 3 | |
| P921 | main subject | schizophrenia | Q41112 |
| teenager | Q1492760 | ||
| P304 | page(s) | 297-307 | |
| P577 | publication date | 2011-05-04 | |
| P1433 | published in | The International Journal of Neuropsychopharmacology | Q7742309 |
| P1476 | title | Cerebellar grey-matter deficits, cannabis use and first-episode schizophrenia in adolescents and young adults | |
| P478 | volume | 15 |
| Q26748778 | A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis |
| Q36354947 | An fMRI Study of Neuronal Activation in Schizophrenia Patients with and without Previous Cannabis Use. |
| Q52625218 | Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders. |
| Q35536880 | Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders. |
| Q30558464 | Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence |
| Q97596506 | Cannabis use in patients with early psychosis is associated with alterations in putamen and thalamic shape |
| Q91705747 | Cannabis use in youth is associated with limited alterations in brain structure |
| Q38124448 | Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings |
| Q34350080 | Developmental trajectory of the endocannabinoid system in human dorsolateral prefrontal cortex |
| Q57464939 | Diverse definitions of the early course of schizophrenia-a targeted literature review |
| Q34290364 | Drugs of abuse and increased risk of psychosis development. |
| Q34638855 | Effect of long-term cannabis use on axonal fibre connectivity |
| Q27001542 | Effects of cannabis on impulsivity: a systematic review of neuroimaging findings |
| Q34282907 | Effects of cannabis use on human brain structure in psychosis: a systematic review combining in vivo structural neuroimaging and post mortem studies |
| Q35836722 | Evaluating the impact of cannabis use on thalamic connectivity in youth at clinical high risk of psychosis |
| Q48144821 | Long-term behavioral and biochemical effects of an ultra-low dose of Δ9-tetrahydrocannabinol (THC): neuroprotection and ERK signaling |
| Q37358080 | MAPK14 and CNR1 gene variant interactions: effects on brain volume deficits in schizophrenia patients with marijuana misuse |
| Q21559698 | Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings |
| Q34531537 | The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability |
| Q24601890 | The endocannabinoid system, cannabinoids, and pain |
| Q37061404 | The neural correlates of mental rotation abilities in cannabis-abusing patients with schizophrenia: an FMRI study |
| Q34326515 | The pharmacologic and clinical effects of medical cannabis. |
| Q33638542 | Δ9-tetrahydrocannabinol prevents methamphetamine-induced neurotoxicity |
Search more.